German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at about 11 euros per share,

Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock. Luxembourg-based private equity firm Triton acquired a total of 17,730,913 ordinary shares in a series of transactions totaling 131 million euros ($140.4 million), the German biotechnology company said.

Triton Partners, is considering a takeover bid Evotec , Eyk Henning of Bloomberg reported earlier, citing people familiar with the matter. Triton is among several investment firms

(Reuters) -Shares in Evotec soared 22% on Monday after private equity firm Triton confirmed a close to 10% stake in the German drug development company, and a media report said it was weighing a takeover bid.

Updates shares, adds further details. Evotec SE (NASDAQ:EVO) ADRs surged 18% after a report that Triton Partners is considering a takeover offer for the German drug developer. Triton is among one of several investment companies that have been looking at a potential deal for Evotec (EVO) in recent months,